The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury

References

• Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56–67.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discovery. 2004;3(8):711–716.
   PubMed Web of Science ®Google Scholar
• Brody T. Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Cambridge, Massachusetts: Academic press; 2016.
   Google Scholar
• Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4(6):489–499.
   PubMed Web of Science ®Google Scholar
• Raunio H. In silico toxicology–non-testing methods. Front Pharmacol. 2011;2:33.
   PubMed Web of Science ®Google Scholar
• Nendza M, Gabbert S, Kühne R, et al. A comparative survey of chemistry-driven in silico methods to identify hazardous substances under REACH. Regul Toxicol Pharmacol. 2013;66(3):301–314.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang J, Wang Y, et al. The liver toxicity knowledge base: a systems approach to a complex end point. Clin Pharmacol Ther. 2013;93(5):409–412.
   PubMed Web of Science ®Google Scholar
• Chen M, Vijay V, Shi Q, et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15):697–703.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase™. Drug Safety. 2010;33(6):503–522.
   PubMed Web of Science ®Google Scholar
• Guo JJ, Wigle PR, Lammers K, et al. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Soc Administ Pharm. 2005;1(3):460–479.
   PubMedGoogle Scholar
• Xu JJ, Henstock PV, Dunn MC, et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci. 2008;105(1):97–105.
   PubMed Web of Science ®Google Scholar
• Greene N, Fisk L, Naven RT, et al. Developing structure− activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23(7):1215–1222.
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, Thakkar S, et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21(4):648–653.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug‐induced liver injury. Hepatology. 2013;57(3):873–874.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(D1):D1091–D1097.
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Foster AJ, Sarda S, et al. A correlation between the in vitro drug toxicity of drugs to cell lines which express human P450s and their propensity to cause liver injury in humans. Toxicol Sci. 2013;137:189–211.
   Google Scholar
• Zhang J, Doshi U, Suzuki A, et al. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact. 2016;255:3–11.
   Web of Science ®Google Scholar
• O’brien P, Irwin W, Diaz D, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006;80(9):580–604.
   PubMed Web of Science ®Google Scholar
• Sipes NS, Martin MT, Kothiya P, et al. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013;26(6):878–895.
   PubMed Web of Science ®Google Scholar
• Berg N, De Wever B, Fuchs HW, et al. Toxicology in the 21st century–working our way towards a visionary reality. Toxicol Vitro. 2011;25(4):874–881.
   PubMed Web of Science ®Google Scholar
• Uehara T, Ono A, Maruyama T, et al. The Japanese toxicogenomics project: application of toxicogenomics. Mol Nutr Food Res. 2010;54(2):218–227.
   PubMed Web of Science ®Google Scholar
• Ganter B, Tugendreich S, Pearson CI, et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol. 2005;119(3):219–244.
   PubMed Web of Science ®Google Scholar
• Liu Z, Shi Q, Ding D, et al. Translating clinical findings into knowledge in drug safety evaluation-drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7(12):e1002310.
   PubMed Web of Science ®Google Scholar
• Yu K, Geng X, Chen M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42(4):744–750.
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–514.
   PubMed Web of Science ®Google Scholar
• Hong H, Tong W, Xie Q, et al. An in silico ensemble method for lead discovery: decision forest. SAR QSAR Environ Res. 2005;16(4):339–347.
   PubMed Web of Science ®Google Scholar
• Hong H, Xie Q, Ge W, et al. Mold2, molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model. 2008;48(7):1337–1344.
   PubMed Web of Science ®Google Scholar
• Muster W, Breidenbach A, Fischer H, et al. Computational toxicology in drug development. Drug Discov Today. 2008;13(7):303–310.
   PubMed Web of Science ®Google Scholar
• Chen M, Hong H, Fang H, et al. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Toxicol Sci. 2013;136:242–249.
   Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury. Hepatology. 2013;58(1):388–396.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. A model to predict severity of drug‐induced liver injury in humans. Hepatology. 2016;64(3):931–940.
   PubMed Web of Science ®Google Scholar